- Home
- ENVB vs KTTA Comparison
ENVB vs KTTA Comparison
Compare ENVB & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- KTTA
- Stock Information
- Founded
- ENVB 1994
- KTTA 2020
- Country
- ENVB United States
- KTTA United States
- Employees
- ENVB N/A
- KTTA N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- KTTA Health Care
- Exchange
- ENVB Nasdaq
- KTTA Nasdaq
- Market Cap
- ENVB 3.3M
- KTTA 2.6M
- IPO Year
- ENVB N/A
- KTTA 2021
- Fundamental
- Price
- ENVB $1.36
- KTTA $1.30
- Analyst Decision
- ENVB
- KTTA
- Analyst Count
- ENVB 0
- KTTA 0
- Target Price
- ENVB N/A
- KTTA N/A
- AVG Volume (30 Days)
- ENVB 564.4K
- KTTA 3.3M
- Earning Date
- ENVB 03-25-2025
- KTTA 03-28-2025
- Dividend Yield
- ENVB N/A
- KTTA N/A
- EPS Growth
- ENVB N/A
- KTTA N/A
- EPS
- ENVB N/A
- KTTA N/A
- Revenue
- ENVB N/A
- KTTA N/A
- Revenue This Year
- ENVB N/A
- KTTA N/A
- Revenue Next Year
- ENVB N/A
- KTTA N/A
- P/E Ratio
- ENVB N/A
- KTTA N/A
- Revenue Growth
- ENVB N/A
- KTTA N/A
- 52 Week Low
- ENVB $1.26
- KTTA $1.25
- 52 Week High
- ENVB $657.00
- KTTA $9.25
- Technical
- Relative Strength Index (RSI)
- ENVB 16.91
- KTTA 30.34
- Support Level
- ENVB $1.26
- KTTA $1.32
- Resistance Level
- ENVB $1.70
- KTTA $1.38
- Average True Range (ATR)
- ENVB 0.17
- KTTA 0.26
- MACD
- ENVB 2.34
- KTTA -0.05
- Stochastic Oscillator
- ENVB 12.20
- KTTA 1.92
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.